St. John's Wort — Research Profile

What the Research Says

St. John's Wort has been studied in clinical trials for mild-to-moderate depressive symptoms across a substantial evidence base. A landmark Cochrane Collaboration review (Linde et al., 2008) analyzed 29 randomized controlled trials (RCTs) involving 5,489 patients and found St. John's Wort extracts superior to placebo, with fewer trial discontinuations for adverse events in the St. John's Wort arms than in the active-comparator arms. A meta-analysis by Ng et al. (2017) of 27 trials (n=3,808) reported similar trial improvements on depression scales between St. John's Wort and SSRI comparator arms in mild-to-moderate depression, with fewer reported discontinuations for adverse events in the St. John's Wort arms. Some trials report symptom-score improvements, but St. John's Wort is not a substitute for prescribed psychiatric care.

The primary active compound, hyperforin, inhibits the reuptake of multiple neurotransmitters — serotonin, norepinephrine, dopamine, GABA, and glutamate — through TRPC6 channel activation (Muller et al., 1998). This mechanism is pharmacologically distinct from single-target SSRIs but does not establish clinical superiority or interchangeability with prescribed antidepressants. St. John's Wort is also a potent inducer of CYP3A4 and P-glycoprotein, which metabolize approximately 50% of prescription medications, producing major drug-drug interactions (Moore et al., 2000). The interaction risk is clinically important, especially with antidepressants (serotonin syndrome), oral contraceptives (contraceptive failure), anticoagulants (warfarin), transplant drugs (immunosuppressant levels), HIV antiretrovirals, and other CYP/P-gp substrates — documented consequences include organ transplant rejection, HIV treatment failure, and unplanned pregnancies.

St. John's Wort is approved by the German Commission E and the European Medicines Agency for mild-to-moderate depression with the requirement of drug-interaction screening. A reanalysis by Kasper et al. (2010) of trial data for the WS 5570 extract reported fewer adverse events in the St. John's Wort arm than in the paroxetine comparator arm, but does not establish clinical superiority. A systematic review by Apaydin et al. (2016) of 35 studies (n=6,993) found St. John's Wort more effective than placebo for mild-to-moderate depression with fewer reported adverse events than antidepressant comparator arms, though the overall evidence quality was rated moderate.

In summary, St. John's Wort has clinical-trial evidence for mild-to-moderate depressive symptoms but is not a substitute for prescribed psychiatric care, and its serious medication-interaction risk requires prescriber review before any use.

Benefits of St. John's Wort

• Mild-to-moderate depressive symptoms (Cochrane review) — Linde et al. (2008) analyzed 29 RCTs with 5,489 patients and found St. John's Wort extracts superior to placebo, with fewer trial discontinuations for adverse events in the St. John's Wort arms than in the active-comparator arms. This Cochrane finding does not establish St. John's Wort as a clinical replacement for prescribed antidepressants; St. John's Wort has major medication-interaction risk and should be disclosed to a prescriber before use
• Citalopram head-to-head trial (Gastpar 2006) — a 6-week double-blind RCT compared 900mg/day St. John's Wort extract (STW 3-VI) to 20mg/day citalopram in 388 patients with moderate depression; both arms showed similar improvements on depression scales, with fewer reported side effects in the St. John's Wort arm. Caveat: this single trial finding does not establish St. John's Wort as a clinical replacement for SSRIs, and combining the two carries a serotonin-syndrome risk — never use both without prescriber guidance
• Multi-target neurotransmitter modulation (mechanism) — Hyperforin, the primary active compound, inhibits reuptake of serotonin, norepinephrine, dopamine, GABA, and glutamate through activation of TRPC6 ion channels. This pharmacology is mechanistically distinct from single-target SSRIs but does not establish clinical superiority or interchangeability with prescribed antidepressants; the multi-target serotonergic activity also raises the risk of serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, tramadol, or other serotonergic medications
• Anxiety reduction — Kobak et al. (2005) demonstrated that St. John's Wort significantly reduced symptoms in patients with generalized social anxiety disorder, and multiple depression trials report anxiety symptom improvement as a secondary outcome
• Seasonal affective disorder (SAD) support — Kasper (1997) reviewed evidence suggesting St. John's Wort's combined antidepressant and mild MAO-inhibiting properties make it particularly suited for winter depression, where serotonin and melatonin dysregulation play central roles

Side Effects and Safety

Safety profile: Caution Needed

Potential Side Effects

• Photosensitivity — increased sensitivity to sunlight and UV radiation; can cause sunburn, rash, or blistering at standard doses in fair-skinned individuals; use sunscreen and avoid prolonged sun exposure
• GI discomfort (nausea, dry mouth, diarrhea) — mild and usually transient; taking with food reduces incidence
• Dizziness and headache — reported in 2-5% of clinical trial participants; typically resolves within first week
• Vivid dreams or insomnia — due to neurotransmitter modulation; taking last dose with dinner (not bedtime) may help
• Serotonin syndrome risk when combined with serotonergic drugs — potentially life-threatening; see drug interactions
• Hypomania or mania in individuals with undiagnosed bipolar disorder — St. John's Wort can trigger manic episodes, as can all antidepressants

Drug & Supplement Interactions

• SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine) — NEVER combine; risk of serotonin syndrome, a potentially fatal condition
• Oral contraceptives — St. John's Wort induces CYP3A4, reducing contraceptive hormone levels; breakthrough bleeding and unplanned pregnancies documented
• Warfarin and anticoagulants — CYP induction reduces warfarin levels, decreasing anticoagulation and increasing clot risk
• HIV antiretrovirals (indinavir, efavirenz, nevirapine) — CYP3A4 induction can reduce drug levels by 50-60%, risking treatment failure and viral resistance
• Immunosuppressants (cyclosporine, tacrolimus) — CYP3A4 induction can cause acute organ rejection in transplant patients
• Digoxin — P-glycoprotein induction reduces digoxin levels, potentially causing cardiac arrhythmia management failure
• Theophylline, anti-seizure medications, chemotherapy agents — all metabolized by CYP3A4; levels reduced by SJW co-administration